News Release

CINCINNATI--(BUSINESS WIRE)--Nov. 27, 2017-- Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced a proposed secondary offering of 4,000,000 shares of its common stock by investment funds affiliated with Cinven Capital Management (V) General Partner Limited (the “Selling Shareholder”). In addition, the Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock from the Selling Shareholder. The offering consists entirely of secondary shares of common stock to be sold by the Selling Shareholder. Medpace will not receive any proceeds from the sale of the shares of common stock by the Selling Shareholder.

Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as bookrunners for the offering.

The offering will be made only by means of a prospectus supplement and an accompanying prospectus. Copies of the prospectus supplement, when available, and the accompanying prospectus relating to this offering may be obtained by contacting:

• Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, via telephone: 1-877-821-7388, or via email: Prospectus_Department@Jefferies.com; or
• Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, via telephone: 1-800-221-1037, or via email: newyork.prospectus@credit-suisse.com.

A registration statement on Form S-3 (including a prospectus) relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people across 35 countries.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171127005988/en/

Source: Medpace Holdings, Inc.

Medpace Holdings, Inc.
Media Contact:
Mary Kuramoto, 513-579-9911 x12523
m.kuramoto@medpace.com
or
Investor Contact:
investor@medpace.com